瑞巴派特联合常规四联疗法治疗幽门螺杆菌阳性消化性溃疡患者的效果

Effects of Rebamipide combined with conventional quadruple therapy in treatment of patients with Helicobacter pylori positive peptic ulcer

目的:观察瑞巴派特联合常规四联疗法治疗幽门螺杆菌(Hp)阳性消化性溃疡患者的效果。方法:回顾性分析2021年1月至2023年6月该院收治的78例Hp阳性消化性溃疡患者的临床资料,根据治疗方法不同将其分为对照组和观察组各39例。对照组予以常规四联疗法治疗,观察组在对照组基础上联合瑞巴特派治疗,比较两组临床疗效,治疗前后胃肠激素指标[生长抑素(SS)、胆囊收缩素(CCK)、血管活性肠肽(VIP)]、炎性因子[基质金属蛋白酶-9(MMP-9)、可溶性血管细胞黏附因子-1(sVCAM-1)、C反应蛋白(CRP)、前列腺素E2(PGE2)]水平,Hp清除率,复发率,以及不良反应发生率。结果:观察组治疗总有效率为94.87%(37/39),高于对照组的79.49%(31/39),差异有统计学意义(P<0.05);治疗后,两组SS水平均高于治疗前,且观察组高于对照组,两组CCK、VIP水平均低于治疗前,且观察组低于对照组,差异有统计学意义(P<0.05);治疗后,两组PGE2水平均高于治疗前,且观察组高于对照组,两组MMP-9、sVCAM-1、CRP水平均低于治疗前,且观察组低于对照组,差异有统计学意义(P<0.05);观察组Hp清除率高于对照组,复发率低于对照组,差异均有统计学意义(P<0.05);两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论:瑞巴派特联合常规四联疗法治疗Hp阳性消化性溃疡患者,可提高临床疗效和Hp清除率,调节胃肠激素指标水平,减轻机体炎症反应,降低复发率,效果优于单纯常规四联疗法。

Objective:To observe effects of Rebamipide combined with conventional quadruple therapy on patients with Helicobacter pylori(Hp)positive peptic ulcer.Methods:The clinical data of 78 patients with Hp positive peptic ulcer admitted to this hospital from January 2021 to June 2023 were retrospectively analyzed.According to different treatment methods,they were divided into control group and observation group,39 cases in each group.The control group was treated with conventional quadruple therapy,while the observation group was treated with Rebamipide on the basis of that of the control group.The clinical efficacy,the levels of gastrointestinal hormone indexes[somatostatin(SS),cholecystokinin(CCK),vasoactive intestinal peptide(VIP)]and inflammatory factors[matrix metalloproteinase-9(MMP-9),soluble vascular cell adhesion factor-1(sVCAM-1),C-reactive protein(CRP),prostaglandin E2(PGE2)]before and after the treatment,the Hp clearance rate,the recurrence rate,and the incidence of adverse reactions were compared between the two groups.Results:The total effective rate of the observation group was 94.87%(37/39),which was higher than 79.49%(31/39)of the control group,and the difference was statistically significant(P<0.05).After the treatment,the SS levels of the two groups were higher than those before the treatment,and that in the observation group was higher than that in the control group;the levels of CCK and VIP in the two groups were lower than those before the treatment,and those in the observation group were lower than those in the control group;and the differences were statistically significant(P<0.05).After the treatment,the levels of PGE2 in the two groups were higher than those before the treatment,and that in the observation group was higher than that in the control group;the levels of MMP-9,sVCAM-1 and CRP in the two groups were lower than those before the treatment,and those in the observation group were lower than those in the control group;and the differences were statistically significant(P<0.05).The Hp clearance rate of the observation group was higher than that of the control group,the recurrence rate was lower than that of the control group,and the differences were statistically significant(P<0.05).However,there was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusions:Rebamipide combined with conventional quadruple therapy in the treatment of the Hppositive peptic ulcer patients can improve the clinical efficacy and the Hp clearance rate,regulate the levels of gastrointestinal hormones,reduce the body’s inflammatory response,and reduce the recurrence rate.Moreover,it is superior to simple conventional quadruple therapy.